Researchers at the University of Kragujevac conducted experiments on 20 laboratory rats.
Researchers said, “Effectiveness was seen from the 14th day of administration… “Possibility of immunotherapy”
GLP-1RA refers to obesity treatment drugs such as ‘WeGobee’ and ‘Ozempic’ from Danish pharmaceutical company Novo Nordisk, which have been cited as the secret to weight loss by Tesla CEO Elon Musk and famous model Kim Kardashian. The ingredient is semaglutide, which has a similar effect to the GLP-1 hormone secreted in the intestines when you eat food, suppressing appetite by making you feel full even if you eat less food.
On the 18th, researchers at the University of Kragujevac in Serbia, Sladjana Pavlovic, announced that they had confirmed this after conducting a study on 20 laboratory rats aged 8 to 10 weeks.
As a result, the semaglutide treatment group showed a delayed onset of breast cancer compared to the control group. The researchers explained, “The tumors in the semaglutide-administered group were consistently smaller than the control group throughout the experiment,” and “a significant difference was observed 14 days after semaglutide administration.”
There was also less evidence of cancer metastasizing to other tissues. In the control group, metastasis occurred in all 10 out of 10 experimental rats, but in the semaglutide group, only 5 out of 10 mice developed metastasis.
The researchers explained, “Semaglutide has potential as an immunotherapy agent for breast cancer,” adding, “However, additional research is needed to determine whether the results of research on mice can be applied to humans.”
Meanwhile, the results of this study were published in the November issue of the international academic journal ‘Biomedicine & pharmacotherapy’.
(Seoul = News 1)
-
- great
- 0dog
-
- I’m sad
- 0dog